Cargando…
The role of (18)F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using (131)I-rituximab as consolidation therapy
PURPOSE: To evaluate the prognostic value of pretreatment (18)F-FDG PET/CT after consolidation therapy of (131)I-rituximab in patients with diffuse large B-cell lymphoma (DLBCL) who had acquired complete remission after receiving chemotherapy. METHODS: Patients who were diagnosed with DLBCL via hist...
Autores principales: | Choi, Joon Ho, Lim, Ilhan, Byun, Byung Hyun, Kim, Byung Il, Choi, Chang Woon, Kang, Hye Jin, Shin, Dong-Yeop, Lim, Sang Moo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512194/ https://www.ncbi.nlm.nih.gov/pubmed/36156599 http://dx.doi.org/10.1371/journal.pone.0273839 |
Ejemplares similares
-
Early response monitoring of neoadjuvant chemotherapy using [(18)F]FDG PET can predict the clinical outcome of extremity osteosarcoma
por: Lee, Inki, et al.
Publicado: (2020) -
Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma
por: Buchegger, Franz, et al.
Publicado: (2011) -
Prediction of Neoadjuvant Chemotherapy Response in Osteosarcoma Using Convolutional Neural Network of Tumor Center (18)F-FDG PET Images
por: Kim, Jingyu, et al.
Publicado: (2021) -
Standard Operating Procedure for In-house Preparation of (131)I-rituximab for Radioimmunotherapy of Non-Hodgkin's Lymphoma
por: Pickford, Matthew D., et al.
Publicado: (2012) -
Standard Operating Procedure for Prospective Individualised Dosimetry for ([131])I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma
por: Calais, Phillipe J., et al.
Publicado: (2012)